VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Vaccine Mechanisms
Vaximmutordb
Vaxism
Vaxar
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UMMS Logo

Vaccine Detail

2011–2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008).
Vaccine Information
  • Vaccine Name: 2011–2012 trivalent inactivated vaccine (A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008).
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004810
  • Type: Inactivated or "killed" vaccine
  • Status: Licensed
  • Host Species for Licensed Use: Baboon
  • Immunization Route: Intramuscular injection (i.m.)
Host Response

Human Response

  • Vaccination Protocol: Volunteer recruitment and vaccination protocols for this study were approved by the Vanderbilt Institutional Review Board (IRB#111030 “CLR-03 2011-Immune Cells and Soluble Factors from Healthy Donor”). After obtaining written informed consent, thirty one subjects were enrolled in this study. Twenty-nine subjects provided 90mL blood samples to develop our phenotyping and cell sorting protocols and to establish baseline blood profiling information; for these purposes, twenty three subjects provided a single blood sample, and six subjects provided four samples over subsequent days on the same schedule as proposed for vaccinated subjects. Once the cell sorting pipeline was in place, two subjects were vaccinated with a single dose of 2011–2012 seasonal trivalent inactivated influenza vaccine (TIV) (strains included: A/California/7/09 (H1N1,), A/Perth /16/2009 (H3N2), and B/Brisbane/60/2008). Blood samples (90mL) from the two vaccinated subjects were processed prior to vaccination (day 0) and at days 1, 3, and 7 post-vaccination for downstream RNA-seq and quantitative proteomics analysis. (Hoek et al., 2015)
  • Host CXCR3 response
    • Description: CXCR3, the receptor for CXCL10/IP-10, was significantly up-regulated in both PBMC and sorted B cell samples after TIV vaccination(Hoek et al., 2015).
    • Detailed Gene Information: Click Here.
  • Host TNFRSF17 response
    • Description: The 2011-2012 TIV vaccine induced upregulation of TNFRSF17 in sorted B cell samples from both subjects 7 days after vaccination (Hoek et al., 2015).
    • Detailed Gene Information: Click Here.
  • Host XBP1 response
    • Description: The 2011-2012 TIV vaccine induced upregulation of XBP1 in sorted B cell samples from both subjects 7 days after vaccination
    • Detailed Gene Information: Click Here.
References
Hoek et al., 2015: Hoek KL, Samir P, Howard LM, Niu X, Prasad N, Galassie A, Liu Q, Allos TM, Floyd KA, Guo Y, Shyr Y, Levy SE, Joyce S, Edwards KM, Link AJ. A cell-based systems biology assessment of human blood to monitor immune responses after influenza vaccination. PloS one. 2015; 10(2); e0118528. [PubMed: 25706537].